<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="38511"><DrugName>aleglitazar</DrugName><DrugNamesKey><Name id="42867858">aleglitazar</Name></DrugNamesKey><DrugSynonyms><Name><Value>R-1439</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>aleglitazar</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>RO-0728804</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dual PPAR agonist (type 2 diabetes, oral), Roche</Value></Name><Name><Value>PPAR alpha/gamma agonist (type 2 diabetes, oral), Roche</Value></Name><Name><Value>RG-1439</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>475479-34-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19446">Roche Holding AG</CompanyOriginator><CompaniesSecondary><Company id="19446">Roche Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="38511" type="Drug"><TargetEntity id="330417" type="siDrug">Aleglitazar</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2480" type="Action"><TargetEntity id="895" type="Mechanism">PPARgamma Agonists</TargetEntity></SourceEntity><SourceEntity id="3033" type="Action"><TargetEntity id="893" type="Mechanism">PPARalpha Agonists</TargetEntity><TargetEntity id="2789" type="Mechanism">PPARalpha Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-01593" type="ciTarget"><TargetEntity id="56349841754653" type="siTarget">Peroxisome proliferator-activated receptor alpha</TargetEntity><TargetEntity id="609" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01596" type="ciTarget"><TargetEntity id="125063490854683" type="siTarget">Peroxisome proliferator-activated receptor gamma</TargetEntity><TargetEntity id="611" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="57">Cardiovascular disease</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="3033">PPAR alpha agonist</Action><Action id="2480">PPAR gamma agonist</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-27T04:02:00.000Z</LastModificationDate><ChangeDateLast>2016-12-20T00:00:00.000Z</ChangeDateLast><AddedDate>2002-03-01T12:58:07.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; was developing aleglitazar (RG-1439; R-1439; RO-0728804), an oral dual  PPAR alpha and gamma agonist, for the potential risk reduction of  cardiovascular disease in high-risk patients with type 2 diabetes [&lt;ulink linkID="463590" linkType="reference"&gt;463590&lt;/ulink&gt;], [&lt;ulink linkID="814242" linkType="Reference"&gt;814242&lt;/ulink&gt;], [&lt;ulink linkID="1027961" linkType="Reference"&gt;1027961&lt;/ulink&gt;]. By March 2010, enrollment in a global phase III trial was underway [&lt;ulink linkID="1083167" linkType="Reference"&gt;1083167&lt;/ulink&gt;], [&lt;ulink linkID="1083854" linkType="Reference"&gt;1083854&lt;/ulink&gt;]. In October 2012, two further phase III trials were expected to start by the end of the year, to assess cardiovascular risk reduction in patients with stable cardiovascular disease and type 2 diabetes or pre-diabetes, and glycemic control in patients with type 2 diabetes  [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;], [&lt;ulink linkID="1331995" linkType="Reference"&gt;1331995&lt;/ulink&gt;]. In October 2012, a phase II study was initiated in patients with  uncomplicated type II diabetes mellitus. At that time, the study was expected to complete in  September 2013. However, in July 2013, Roche halted the AleCARDIO trial and all other studies involving aleglitazar due to safety concerns and lack of efficacy following an independent data safety monitoring board (DSMB) analysis. At that time, Roche decided  to discontinue development of the drug [&lt;ulink linkID="1450530" linkType="Reference"&gt;1450530&lt;/ulink&gt;], [&lt;ulink linkID="1450687" linkType="Reference"&gt;1450687&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2010, regulatory filings had been expected in 2014 [&lt;ulink linkID="1085151" linkType="Reference"&gt;1085151&lt;/ulink&gt;]. In October 2012, filings for cardiovascular risk reduction in type 2 diabetes were expected in 2015 [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In May 2013, a randomized, double blind, parallel group, placebo-controlled, multicenter, phase III study (CTR20130332, YC28036, &lt;ulink linkID="137814" linkType="Protocol"&gt;NCT01871415&lt;/ulink&gt;) was initiated in China to evaluate efficacy and safety of aleglitazar plus metformin combination compared with placebo plus metformin in patients (total n = 400, China n = 240) with type II diabetes mellitus treated with  metformin monotherapy. In July 2013, the trial was suspended by the company due to lack of efficacy [&lt;ulink linkID="1487483" linkType="Reference"&gt;1487483&lt;/ulink&gt;], [&lt;ulink linkID="1487486" linkType="Reference"&gt;1487486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a placebo-controlled, phase III trial (AleGlucose) was planned to start in Q4 2012 to study glycemic control in patients (estimated n = 1400) with type 2 diabetes in the US and China [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;], [&lt;ulink linkID="1331995" linkType="Reference"&gt;1331995&lt;/ulink&gt;]. The trial would study aleglitazar as a monotherapy and as an add-on to metformin and/or a sulfonylurea [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;]. However, in July 2013, Roche discontinued all trials of the drug [&lt;ulink linkID="1450530" linkType="Reference"&gt;1450530&lt;/ulink&gt;], [&lt;ulink linkID="1450687" linkType="Reference"&gt;1450687&lt;/ulink&gt;]. In March 2014, clinical data were presented at the 63rd Annual Meeting of the American College of Cardiology in Washington DC. The study was discontinued early due to high incidences of adverse events and there was no difference in the primary endpoint for placebo or aleglitazar groups. The aleglitazar group did show improved levels of triglycerides and HDL-C and reductions in glycated hemoglobin [&lt;ulink linkID="1542293" linkType="Reference"&gt;1542293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a placebo-controlled, phase III trial (AlePrevent) was expected to start in Q4 2012 to assess aleglitazar, with standard of care, for cardiovascular risk reduction in patients (estimated n = 19,000) with stable cardiovascular disease and type 2 diabetes or pre-diabetes [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;], [&lt;ulink linkID="1331995" linkType="Reference"&gt;1331995&lt;/ulink&gt;]. The primary endpoint would be reduction in MACE (major adverse cardiovascular events), and the trial would have at least a 3-year treatment period and continue until 1260 events had occurred  [&lt;ulink linkID="1331904" linkType="Reference"&gt;1331904&lt;/ulink&gt;]. However, in July 2013, Roche discontinued all trials  of the drug [&lt;ulink linkID="1450530" linkType="Reference"&gt;1450530&lt;/ulink&gt;], [&lt;ulink linkID="1450687" linkType="Reference"&gt;1450687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, a  global, phase III, randomized, double-blind, placebo-controlled, safety/efficacy trial (&lt;ulink linkID="63253" linkType="Protocol"&gt;NCT01042769&lt;/ulink&gt;; BC22140; 2009-012269-71; AleCARDIO) began in patients with type 2 diabetes who had recently experienced a cardiac event (n = 6000). The primary endpoint was the effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, with secondary endpoints of glycemic control, lipoprotein profile, blood pressure, and biomarkers of cardiovascular risk. The study was expected to complete in  July 2014 [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;], [&lt;ulink linkID="1083167" linkType="Reference"&gt;1083167&lt;/ulink&gt;], [&lt;ulink linkID="1083854" linkType="Reference"&gt;1083854&lt;/ulink&gt;]. In  October 2010, the trial was expected to have a treatment period of at least 2.5 years and last until 950 events had occurred. Patients would receive 150 microg aleglitazar plus SOC, or a placebo and SOC [&lt;ulink linkID="1139639" linkType="Reference"&gt;1139639&lt;/ulink&gt;]. In May 2012, enrollment was completed with 7229 patients randomized. In September 2012, data were expected in 2015 [&lt;ulink linkID="1320497" linkType="Reference"&gt;1320497&lt;/ulink&gt;]. However, in July 2013, following a DSMB review, the AleCARDIO study was discontinued due to safety concerns that aleglitazar increased the risk of heart failure and kidney impairment, and due to a lack of efficacy [&lt;ulink linkID="1450530" linkType="Reference"&gt;1450530&lt;/ulink&gt;], [&lt;ulink linkID="1450687" linkType="Reference"&gt;1450687&lt;/ulink&gt;]. In August 2010, the trial (CTR20130843) was initiated  in China (n = 630). By November 2013, the trial was  discontinued by Roche because experimental data showed that the efficacy was insufficient and overall risk benefit ration was not ideal [&lt;ulink linkID="1500310" linkType="Reference"&gt;1500310&lt;/ulink&gt;]. In November 2016, further data from the trial were presented at the AHA's Scientific Sessions 2016 in New Orleans, LA. In the univariate analysis (except primary endpoint) and after adjustment for 28 variables including those reflecting insulin resistance and adipocyte function (insulin, glucose, free fatty acids), an increase in adiponectin from baseline to month 3 was adversely associated with cardiovascular outcomes, however no interaction of the change in adiponectin and treatment assignment on any outcome was observed [&lt;ulink linkID="1872033" linkType="Reference"&gt;1872033&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2012, a single-center, double blind, placebo-controlled, randomized, cross-over, phase II study (&lt;ulink linkID="91015" linkType="Protocol"&gt;NCT01680978&lt;/ulink&gt;; BC25445) was initiated in the UK, to assess the effect   of the  drug  on cardiac energetics  and  function in patients (n = 18) with  uncomplicated type II diabetes mellitus and with no history of coronory heart disease. At that time, the study was expected to complete in  September 2013; the study was completed in September 2013  [&lt;ulink linkID="1629363" linkType="Reference"&gt;1629363&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2010, a multinational, randomized, double-blind, parallel-assignment, phase II study (&lt;ulink linkID="63256" linkType="Protocol"&gt;NCT01043029&lt;/ulink&gt;; BC22419; 2009-012270-12; AleNEPHRO) was planned to assess the safety and efficacy of aleglitazar (150 microg) compared to &lt;ulink linkID="4126" linkType="Drug"&gt;pioglitazone&lt;/ulink&gt; (45 mg) in patients with type 2 diabetes and moderate renal impairment (expected n = 300). The primary endpoint was glomerular filtration rate at week 60, with secondary endpoints of glomerular filtration rate at week 52, effect on blood hemoglobin, and safety and tolerability. The study was due to complete in February 2013 [&lt;ulink linkID="1107265" linkType="Reference"&gt;1107265&lt;/ulink&gt;], [&lt;ulink linkID="1118196" linkType="Reference"&gt;1118196&lt;/ulink&gt;]. The study began in 2Q10 [&lt;ulink linkID="1118196" linkType="Reference"&gt;1118196&lt;/ulink&gt;]. Enrollment completed in 2Q11 [&lt;ulink linkID="1279578" linkType="Reference"&gt;1279578&lt;/ulink&gt;]. In September 2012, it was reported that the study had achieved its primary endpoint of no more than a mild decrease in renal function which was reversible [&lt;ulink linkID="1320497" linkType="Reference"&gt;1320497&lt;/ulink&gt;]. Data were presented at the American Society of Nephrology meeting in November 2012. In 302 enrolled patients, the results showed that after 52 weeks of treatment with aleglitazar and 8 weeks follow up after stopping treatment, the average decline in renal function (eGFR, estimated glomerular filtration rate level) was comparable for patients who had received aleglitazar (-2.7%) versus  pioglitazone (-3.4%). The average on-treatment change in eGFR with aleglitazar was -15.0%, compared to -5.4% with pioglitazone. Aleglitazar reduced protein in the urine by 54% by the end of the follow-up period in patients already receiving ACE inhibitors or ARBs and who had macroalbuminuria at the beginning of the study     [&lt;ulink linkID="1454801" linkType="Reference"&gt;1454801&lt;/ulink&gt;]. In June 2013, further data were presented at the ADA 73rd Scientific Sessions in Chicago, IL. Both aleglitazar and pioglitazone showed similar improvements in insulin sensitivity and absolute changes in HbA1c levels. Aleglitazar was associated with superior improvements in lipid parameters compared with pioglitazone [&lt;ulink linkID="1442770" linkType="Reference"&gt;1442770&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, a  randomized, double-blind, active-controlled, parallel-group, phase II trial (&lt;ulink linkID="3333" linkType="Protocol"&gt;NCT00461006&lt;/ulink&gt;; BC20653; SESTA-R)  was initiated in subjects (expected n = 176) with type 2 diabetes in the US, Mexico, Russia and the Ukraine. The subjects were to receive either high-dose aleglitazar po qd  (0.6 mg) or 45 mg of &lt;ulink linkID="4126" linkType="Drug"&gt;pioglitazone&lt;/ulink&gt; po qd. The primary endpoint was the relative change from baseline in glomerular filtration rate. The study was expected to be completed in August 2008  [&lt;ulink linkID="926889" linkType="Reference"&gt;926889&lt;/ulink&gt;], [&lt;ulink linkID="926880" linkType="Reference"&gt;926880&lt;/ulink&gt;], [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;]. Data were published in September 2011. In 118 patients with evaluable GFR measurements, baseline mean mGFR was 97.6  ml/min/1.73 m(2) in the aleglitazar group and 101.9 ml/min/1.73m(2) in the pioglitazone group. Mean percent change from baseline mGFR was -16.9% with aleglitazar and -4.6% with pioglitazone, a mean treatment difference of -13.0%. Following aleglitazar withdrawal, eGFR values returned to pretreatment levels within the 4- to 8-week follow-up [&lt;ulink linkID="1454896" linkType="Reference"&gt;1454896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2006, a comparative, randomized, double-blind, worldwide, phase II trial (&lt;ulink linkID="3329" linkType="Protocol"&gt;NCT00388518&lt;/ulink&gt;; BM17864; SYNCHRONY) had been initiated in patients with type 2 diabetes (n = 332).  Patients were to receive one of four doses of aleglitazar, &lt;ulink linkID="4126" linkType="Drug"&gt;pioglitazone&lt;/ulink&gt; or placebo. The primary endpoint was absolute change from baseline in glycosylated hemoglobin levels. By July 2008 this study had been completed [&lt;ulink linkID="819104" linkType="Reference"&gt;819104&lt;/ulink&gt;]. In June 2009, data were reported, showing that the drug had met the trial's primary and secondary endpoints. In the study, patients received  50, 150, 300 or 600 microg of aleglitazar once-daily, 45 mg of pioglitazone or placebo. The primary endpoint was met, with the 50 and 600 microg doses reducing HbA1c levels by -0.36 and -1.35%, respectively. The 150 microg dose reduced HbA1c levels in a comparable way to pioglitazone. The 50 and 600 microg of aleglitazar also reduced fasting plasma glucose levels by -1 and 3.3 mmol/l, triglyceride levels by -27.8 and 51.6%, and LDL-C levels by -9.1 and 25.9%, respectively. Patients treated with 50 and 300 microg of aleglitazar also experienced an increase in HDL-C levels by 8.2 and 22.9%, respectively. The 150 microg dose reduced triglyceride and LDL-C levels and increased HDL-C levels more effectively than pioglitazone. Known and dose-dependent PPAR-alpha and gamma-associated events were seen, including edema, hemodilution, and weight gain. The incidence of edema in the 150 microg dose group was similar to the placebo group and less than the incidence in the pioglitazone group. Fewer patients receiving 150 microg of aleglitazar gained weight, compared with pioglitazone-treated patients [&lt;ulink linkID="1016666" linkType="Reference"&gt;1016666&lt;/ulink&gt;], [&lt;ulink linkID="1016873" linkType="Reference"&gt;1016873&lt;/ulink&gt;]. In June 2009,  similar data were presented at the 69th ADA scientific sessions in New Orleans, LA [&lt;ulink linkID="1013472" linkType="Reference"&gt;1013472&lt;/ulink&gt;]. In October 2009, the data were also presented at ACC 2009. At the time, data supported a phase III "go" decision [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;]. In November 2009, further data were presented at the AHA Scientific Sessions in Orlando, FL. Reductions in high sensitivity C-reactive protein, plasminogen activator inhibitor 1 and fibrinogen  were observed following treatment with aleglitazar [&lt;ulink linkID="1053730" linkType="Reference"&gt;1053730&lt;/ulink&gt;].  In September 2011,  further data were  presented from a post-hoc subanalysis at the 47th EASD Annual Meeting in Lisbon, Portugal. In the statin-treated (n = 7) and statin-free (n = 48) patients at baseline, aleglitazar (150 mg) therapy reduced LDL-cholesterol by -19.8 and -7.29%, respectively, and triglycerides by -32.91% and -25.68%, respectively, and increased HDL-cholesterol by 26.15 and 23.30%, respectively; improvements were numerically greater in statin-treated patients than statin-free patients [&lt;ulink linkID="1220221" linkType="Reference"&gt;1220221&lt;/ulink&gt;]. In March 2012, post-hoc data were presented at the 61st ACC Meeting in Chicago, IL. Aleglitazar dose-dependently lowered the triglyceride:HDL-cholesterol ratio up to a ceiling dose of 300 microg, which resulted in a decrease by 2.72 compared to 1.31 with pioglitazone [&lt;ulink linkID="1275821" linkType="Reference"&gt;1275821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2011, a  randomized, double-blind, parallel-group, interventional phase I trial (&lt;ulink linkID="79426" linkType="Protocol"&gt;NCT01398267&lt;/ulink&gt;; BP25328) was initiated in the US in patients (expected n = 55) with type 2 diabetes to assess the pharmacokinetics and  pharmacodynamic effect of aleglitazar treated with &lt;ulink linkID="44601" linkType="Drug"&gt;lisinopril&lt;/ulink&gt;. At that time, the trial was expected to complete in October 2012. In January 2013, the trial was completed [&lt;ulink linkID="1634836" linkType="Reference"&gt;1634836&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, a single-center, randomized, double-blind, parallel-group phase I study (&lt;ulink linkID="69518" linkType="Protocol"&gt;NCT01188317&lt;/ulink&gt;; BP25330) was initiated in healthy subjects to evaluate the effect of the coadministration of aleglitazar and ibuprofen on the renal function. The study was expected to be completed in September 2011   [&lt;ulink linkID="1338653" linkType="Reference"&gt;1338653&lt;/ulink&gt;]. In November 2012,  data  were presented at the AHA Scientific Sessions in Los Angeles, CA. Healthy subjects received aleglitazar (150 microg qd; n = 24) or placebo (n = 23) for 33 days, and ibuprofen (800 mg tid) was given to all the subjects from day 30 to 33. In the aleglitazar and placebo groups, following ibuprofen administration, the changes in measured glomerular filtration rate (mGFR) and effective renal plasma flow (EGFR) were not found to be statistically different. Coadministration of aleglitazar and ibuprofen was well tolerated [&lt;ulink linkID="1337873" linkType="Reference"&gt;1337873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2012, data a phase I study (n=44) to study the addition of low-dose aspirin on renal function in aleglitazar-treated patients, were presented at the 61st ACC meeting in Chicago, IL. No impact of the agent on the risk of low-dose aspirin-induced renal dysfunction was seen [&lt;ulink linkID="1275821" linkType="Reference"&gt;1275821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, a  single-center, phase I study (&lt;ulink linkID="95506" linkType="Protocol"&gt;NCT01711775&lt;/ulink&gt;; BP25230) was initiated in China to assess the pharmacokinetics of aleglitazar after administration of single and multiple oral doses of 150 microg tablet in Chinese adults (n = 16). The trial completed in January 2013 [&lt;ulink linkID="1389332" linkType="Reference"&gt;1389332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, clinical data were presented at the AHA Scientific Sessions in Orlando, FL. Steady-state pharmacokinetics were not affected following coadministration of &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin&lt;/ulink&gt;  (80 mg/day) or &lt;ulink linkID="12420" linkType="Drug"&gt;rosuvastatin&lt;/ulink&gt; (40 mg/day) with aleglitazar (80 mg/day) [&lt;ulink linkID="1054395" linkType="Reference"&gt;1054395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I trials were underway by March 2003 [&lt;ulink linkID="485279" linkType="reference"&gt;485279&lt;/ulink&gt;], [&lt;ulink linkID="488058" linkType="reference"&gt;488058&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2013, preclinical data presented at the 2013 ESC Congress in Amsterdam, the Netherlands, showed that aleglitazar augmented number, function and survival of EPC in mouse models [&lt;ulink linkID="1472235" linkType="Reference"&gt;1472235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, preclinical data were presented at the 2013 ARVO Meeting in Seattle, WA.    At high-dose, aleglitazar significantly decreased diabetes-induced retinal vascular hyperpermeability in diabetic rats when compared with control.  Aleglitazar significantly decreased diabetes-induced increases in adherent leukocytes in a dose-dependent manner in diabetic rat retina [&lt;ulink linkID="1413148" linkType="Reference"&gt;1413148&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2009, data were presented at the AHA Scientific Sessions in Orlando, FL, showing that aleglitazar was efficacious in lipid-modulating in a rhesus monkey model of type 2 diabetes, and also displayed anti-atherogenic properties [&lt;ulink linkID="1054544" linkType="Reference"&gt;1054544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, data presented at the 2012 ESC congress in Munich, Germany, showed that aleglitazar exerted protective vascular mechanisms in mice, including improvement of endothelial function and upregulation of both number and functionality of endothelial progenitor cells [&lt;ulink linkID="1317538" linkType="Reference"&gt;1317538&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, preclinical data  presented at the 237th ACS meeting in Salt Lake City, UT, showed that aleglitazar had an excellent in vitro and in vivo profile [&lt;ulink linkID="993528" linkType="Reference"&gt;993528&lt;/ulink&gt;], [&lt;ulink linkID="986398" linkType="Reference"&gt;986398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2009, a series of substituted 3-(4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl)-propionic acids as dual  PPAR alpha and gamma agonists had been synthesized and evaluated. One of the most promising compounds, aleglitazar had IC50 values of 0.038 and 0.19 microM for PPAR alpha and gamma, respectively. The compound also had EC50 values of 0.050 and 0.021 microM for PPAR alpha and gamma, respectively [&lt;ulink linkID="1003790" linkType="Reference"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2012, the EMA's Paediatric Committee confirmed the applicability of a class waiver for  type 2 diabetes and coronary atherosclerosis [&lt;ulink linkID="1351513" linkType="Reference"&gt;1351513&lt;/ulink&gt;]. In April 2013, the Pediatrics Committee of the EMA planned to discuss the applicability of a class waiver for the delay of type 2 diabetes in subjects with cardiovascular disease and pre-diabetes, at a meeting scheduled for April 10 to 12, 2013 [&lt;ulink linkID="1401169" linkType="Reference"&gt;1401169&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Beata Lecka-Czernik, University of Toledo, College of Medicine, Toledo, USA&lt;/para&gt;&lt;para&gt;Submission date: 20 August 2010&lt;br/&gt;Publication date: 06 December 2010&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;PPARgamma and PPARalpha are nuclear receptors mainly involved in the regulation of glucose homeostasis and lipid levels, respectively. Aleglitazar, being developed by &lt;ulink linkType="Company" linkID="19446"&gt;Roche Holding&lt;/ulink&gt;, is a dual agonist for PPARgamma and PPARalpha for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (T2DM). In preclinical studies, aleglitazar decreased non-fasted glucose levels, increased glucose clearance and improved insulin resistance, while also increasing HDL-cholesterol and decreasing LDL-cholesterol levels in serum. In phase I and II clinical trials in patients with T2DM, aleglitazar demonstrated beneficial antidiabetic activities and had a higher antihyperglycemic efficacy than &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (a PPARgamma agonist). Aleglitazar improved the lipid profile in patients and decreased levels of cardiovascular markers of inflammation and clotting. The observed adverse events were characteristic of either PPARgamma or PPARalpha agonists; however, when compared to &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;-PPARgamma-mediated effects, such as edema and weight gain, these were less severe. PPARgamma-mediated adverse events on bone have not been measured and should be addressed in the future. The PPARalpha-mediated adverse effects on renal function are of concern and are a primary endpoint of ongoing phase II clinical trials in patients with T2DM. A phase III clinical trial was also ongoing in patients with T2DM who had recently experienced a cardiac event.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;By the end of 2009, diabetes affected more than 220 million individuals worldwide and is prevalent in all ages, including very young children [&lt;ulink linkType="Reference" linkID="1071452"&gt;1071452&lt;/ulink&gt;]. The most common form of diabetes is insulin independent, known as type 2 diabetes mellitus (T2DM). T2DM is characterized by insulin and glucose intolerance, and is associated with the development of hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure; cardiovascular disease in patients with T2DM accounts for 50% of all deaths in this patient population [&lt;ulink linkType="Reference" linkID="1071452"&gt;1071452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Available antidiabetic therapies include insulin, insulin secretagogues (eg, sulfonylureas) and glucose-lowering drugs (eg, thiazolidinediones [TZDs], biguanide and incretins) [&lt;ulink linkType="Reference" linkID="1129585"&gt;1129585&lt;/ulink&gt;]. Of these, only TZDs have insulin-sensitizing properties and are the most efficient in the management of poorly controlled diabetes [&lt;ulink linkType="Reference" linkID="1129585"&gt;1129585&lt;/ulink&gt;]. TZDs are agonists of the nuclear receptor PPARgamma, a key regulator of insulin signaling, and glucose and fat metabolism [&lt;ulink linkType="Reference" linkID="1129591"&gt;1129591&lt;/ulink&gt;]. PPARgamma is mainly expressed in the adipose tissue and the functions of PPARgamma include the production of proteins involved in carbohydrate and fatty acid metabolism, and the production of adipokines (specific cytokines in fat tissue), such as leptin and adiponectin, which regulate insulin sensitivity in peripheral tissues [&lt;ulink linkType="Reference" linkID="579216"&gt;579216&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129591"&gt;1129591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The transcriptional activity of PPARgamma is controlled by the binding of lipophilic ligands to the ligand-binding pocket of PPARgamma. Natural ligands of PPARgamma are derived from nutrients or products of metabolic pathways and consist of polyunsaturated fatty acid derivatives and eicosanoids [&lt;ulink linkType="Reference" linkID="1129591"&gt;1129591&lt;/ulink&gt;]. Synthetic ligands, such as TZDs, bind to PPARgamma with high affinity, activate its adipogenic activity and act as insulin sensitizers [&lt;ulink linkType="Reference" linkID="420811"&gt;420811&lt;/ulink&gt;]. Two FDA-approved PPARgamma agonists, &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;, have been in clinical use since 1999 [&lt;ulink linkType="Reference" linkID="327686"&gt;327686&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="338000"&gt;338000&lt;/ulink&gt;]. In addition to improving glycemic control in patients with T2DM, &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; improve lipid metabolism, with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; having a more favorable impact on serum lipids, lipoproteins and apolipoproteins than &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1129615"&gt;1129615&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Several studies demonstrated the superior efficacy of PPARgamma agonists over other available antidiabetic therapies in the control of diabetic hyperglycemia [&lt;ulink linkType="Reference" linkID="756003"&gt;756003&lt;/ulink&gt;]. However, prolonged use of TZDs is associated with several adverse effects. These include fluid retention, anemia and weight gain for both &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;, and this drug class in general [&lt;ulink linkType="Reference" linkID="1129645"&gt;1129645&lt;/ulink&gt;]. There is also strong clinical evidence for a connection between the use of &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and a significant increase in the risk of myocardial infarction and death from cardiovascular causes [&lt;ulink linkType="Reference" linkID="799234"&gt;799234&lt;/ulink&gt;]. This association resulted in a recent review of the safety of &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; by the FDA [&lt;ulink linkType="Reference" linkID="1129710"&gt;1129710&lt;/ulink&gt;]. Interestingly, use of &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; is associated with a significantly lower risk of death from cardiovascular causes and a lower number of myocardial infarction and stroke incidences [&lt;ulink linkType="Reference" linkID="842283"&gt;842283&lt;/ulink&gt;], indicating that cardiovascular effects of TZDs are not a drug class effect, but rather specifically associated with the type of PPARgamma agonist.&lt;/para&gt;&lt;para&gt;Apart from PPARgamma, PPAR receptor subtypes also include PPARalpha and PPARdelta [&lt;ulink linkType="Reference" linkID="579216"&gt;579216&lt;/ulink&gt;]. PPARdelta is expressed ubiquitously and is involved in regulating dyslipidemia and cardiovascular diseases. PPARalpha is expressed predominantly in the liver, and, to a lesser extent, in muscle, heart and tissues affected by diabetic microvascular disease (ie, retina, kidney and nerves) [&lt;ulink linkType="Reference" linkID="579216"&gt;579216&lt;/ulink&gt;]. In the liver, PPARalpha has a crucial role in fatty acid oxidation (regulating plasma lipid levels), which provides energy for peripheral tissues [&lt;ulink linkType="Reference" linkID="1129650"&gt;1129650&lt;/ulink&gt;]. PPARalpha agonists, such as fibrates, belong to the hypolipidemic class of drugs, which stimulate lipid oxidation, decrease circulating triglyceride levels, increase HDL cholesterol and have an anti-atherosclerotic activity [&lt;ulink linkType="Reference" linkID="1129650"&gt;1129650&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129656"&gt;1129656&lt;/ulink&gt;]. Moreover, PPARalpha agonists have a beneficial effect on the prevention of microvascular diseases by inhibiting mediators of vascular damage, such as lipotoxicity, inflammation, reactive oxygen species generation, endothelial dysfunction, angiogenesis and thrombosis [&lt;ulink linkType="Reference" linkID="1129891"&gt;1129891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;T2DM is a complex disease in which hyperglycemia and insulin resistance are often combined with microvascular and cardiovascular diseases. Therefore, a reasonable approach in the treatment of T2DM is a strategy that simultaneously treats insulin resistance and atherogenic dyslipidemia. Research to develop dual agonists that activate insulin-sensitizing properties of PPARgamma and lipid-lowering abilities of PPARalpha is ongoing and several agonists have been investigated, including &lt;ulink linkType="Drug" linkID="33451"&gt;muraglitazar&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt;. However, the development of both these agents has been discontinued because of safety concerns, with &lt;ulink linkType="Drug" linkID="33451"&gt;muraglitazar&lt;/ulink&gt; linked to cardiovascular side effects and &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt; to renal impairment [&lt;ulink linkType="Reference" linkID="630997"&gt;630997&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="665830"&gt;665830&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129746"&gt;1129746&lt;/ulink&gt;]. Another dual PPARalpha/gamma agonist is aleglitazar, being developed by &lt;ulink linkType="Company" linkID="19446"&gt;Roche Holding&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1027961"&gt;1027961&lt;/ulink&gt;]. Aleglitazar has demonstrated beneficial effects on insulin sensitivity as well as anti-atherogenic effects in patients with T2DM in phase I and II clinical trials [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;]. At the time of publication, aleglitazar was being assessed in a phase III trial (ClinicalTrials.gov identifier: &lt;ulink linkType="Protocol" linkID="63253"&gt;NCT01042769&lt;/ulink&gt;) in patients with T2DM who had recently experienced a cardiac event, in phase II trials in patients with T2DM (&lt;ulink linkType="Protocol" linkID="3333"&gt;NCT00461006&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="63256"&gt;NCT01043029&lt;/ulink&gt;) and in phase I trials in healthy volunteers in combination with aspirin (&lt;ulink linkType="Protocol" linkID="69514"&gt;NCT01188304&lt;/ulink&gt;) and ibuprofen (&lt;ulink linkType="Protocol" linkID="69518"&gt;NCT01188317&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Aleglitazar is a novel alpha-alkoxy-beta-arylpropionic acid, which was developed using a structure-based design of indole propionic acid [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1133286"&gt;1133286&lt;/ulink&gt;]. The design of aleglitazar is based on an acidic head linked to an aromatic center, which in turn is linked to a cyclic tail. For the acidic head, alpha-alkoxyacids were chosen because of their pivotal hydrogen bonding with serine, tyrosine and histidine of the PPAR protein. Aryloxazoles were selected for the cyclic tail based on known PPAR agonists (eg, &lt;ulink linkType="Drug" linkID="33451"&gt;muraglitazar&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt;, a PPARalpha/gamma dual agonist with predominant PPARgamma activity), while bicyclic aryls were chosen for the aromatic center because simple phenyl rings were not a good fit for the pocket of the receptor. Optimization of the three groups with different substituents led to the discovery of aleglitazar [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Aleglitazar was synthesized from (S)-4-benzyl-3-methoxy-acetyl-oxazolidin-2-one and 4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophene-7-carbaldehyde via diastereoselective aldol condensation, followed by selective reduction and removal of the chiral auxiliary group [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA170300"&gt;WO-02092084&lt;/ulink&gt;]. The 3-methoxyacetyl derivative of the chiral auxiliary (4S-benzyl-2-oxazolidinone) was prepared by acylation with methoxyacetyl chloride in the presence of butyllithium in cold tetrahydrofuran. The starting aryloxazole-benzo[b]thiophene-7-carbaldehyde was synthesized from butane-2,3-dione-oxime and benzaldehyde and 4-hydroxy-benzo[b]thiophene-7-carbaldehyde according to previously described methods [&lt;ulink linkType="Reference" linkID="1133295"&gt;1133295&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA2958778"&gt;US-07262303&lt;/ulink&gt;]. Aldol condensation was carried out by treating a solution of (S)-4-benzyl-3-methoxyacetyl-oxazolidin-2-one and triethylamine in dichloromethane at -78degC with dibutylboron triflate. The mixture was warmed to 0degC, re-cooled to -78degC after 50 min, and then the starting aryloxazole-benzo[b]-thiophene-7-carbaldehyde was added to give the (2S,3R)-3-hydroxy-2-methoxy-oxazolidinone adduct as the major product. The 3-hydroxy group was reduced with triethylsilane and trifluoroacetic acid, and the chiral auxiliary group was removed using lithium hydroxide in tetrahydrofuran at 35degC to give aleglitazar in good yield [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA170300"&gt;WO-02092084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;Binding affinities of aleglitazar for human PPARalpha and PPARgamma were determined in a competition radioligand binding assay; aleglitazar bound to PPARalpha with an IC50 value of 0.038 microM and to PPARgamma with an IC50 value of 0.019 microM [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. The potency of aleglitazar to activate transcriptional activities of both receptors was assessed in a luciferase transcriptional reporter gene assay; the EC50 values for human PPARalpha- and PPARgamma-specific functional transcriptional transactivation were 0.050 and 0.21 microM, respectively [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Species selectivity of binding of aleglitazar to PPARalpha has been established; aleglitazar bound to human PPARalpha with an EC50 value of 0.050 microM, which was decreased by approximately two orders of magnitude in rats (EC50 = 2.26 microM) and mice (EC50 = 2.34 microM). This finding suggested that PPARalpha-mediated pharmacodynamic effects in rodents might be of lower magnitude compared with effects observed in primates and humans [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In human hepatocytes, the molecular effect of aleglitazar on gene expression was compared with the molecular effects of &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt; (a dual PPARalpha/gamma agonist) and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="55355"&gt;choline fenofibrate&lt;/ulink&gt; (a PPARalpha agonist; the combination thus generating PPARalpha/gamma agonism) [&lt;ulink linkType="Reference" linkID="1046918"&gt;1046918&lt;/ulink&gt;]. All agents were applied at comparable concentrations with respect to receptor activation. Using the Reverse Causal Reasoning (RCR) method and the Causal Network Modeling platform, it was predicted that aleglitazar increased expression of 94 genes regulated by PPARalpha in comparison with 66 genes for &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt; and 75 genes for &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="55355"&gt;choline fenofibrate&lt;/ulink&gt;. The RCR also predicted that aleglitazar and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="55355"&gt;choline fenofibrate&lt;/ulink&gt; would decrease VLDL/LDL and increase HDL synthesis more strongly than &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt;. Interestingly, while &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="55355"&gt;choline fenofibrate&lt;/ulink&gt; induced changes in the expression of genes belonging to the NRF2 (NF-E2-related factor 2)-controlled oxidative stress response pathway, aleglitazar had no effect on the expression of genes controlled by this pathway [&lt;ulink linkType="Reference" linkID="1046918"&gt;1046918&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo&lt;/subtitle&gt;In the db/db murine model of hyperglycemia and insulin resistance, aleglitazar (0.3 or 3 mg/kg/day po for 12 days) was more efficacious than &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; (3 mg/kg/day po for 12 days) in decreasing blood glucose levels and increasing glucose clearance [&lt;ulink linkType="Reference" linkID="986398"&gt;986398&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. Non-fasted glucose levels were significantly decreased with both doses of aleglitazar (glucose level: ~ 12 and 12.5 mM at 0.3 and 3 mg/kg/day of aleglitazar) compared with placebo (glucose level: ~ 22 mM), and the decrease was comparable to that observed with &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; (glucose level: ~ 14 mM). The glucose clearance was measured with an oral glucose tolerance test (oGTT), which was performed on overnight-fasted db/db mice. At ~ 60 min after glucose challenge, peak glucose levels were reduced by ~ 1.6, ~ 1.3- and ~ 2.1--fold with &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and with the 0.3- and 3-mg/kg/day doses of aleglitazar, respectively [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The insulin-sensitizing activity of aleglitazar (1 mg/kg/day po) was compared with &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; (3 mg/kg/day po) and &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt; (10 mg/kg/day po) in a hyperinsulinemic/euglycemic clamp study in the Zucker fatty (fa/fa) rat model of hyperglycemia and insulin resistance [&lt;ulink linkType="Reference" linkID="986398"&gt;986398&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. Aleglitazar increased insulin sensitivity at smaller doses than &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt;, and exhibited superior efficacy to &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt; when the glucose infusion rate (GIR) was measured 7 days after treatment cessation and compared with the GIR in non-treated rats [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. The insulin resistance index was assessed and expressed as a HOMA-IR (homeostasis model assessment index of insulin resistance), which was calculated from fasting plasma insulin and fasting blood glucose levels. Relative to the non-treated rats (HOMA-IR = 1), aleglitazar had a lower HOMA-IR value (~ 0.2) compared with &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; (~ 0.7) and &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt; (~ 0.4), confirming its higher efficacy as an insulin-sensitizing agent [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. Of note, the studies assessed single doses and a definite conclusion regarding the superior efficacy of aleglitazar cannot be drawn until full dose-response curves have been constructed.&lt;/para&gt;&lt;para&gt;The PPARalpha-mediated cardiovascular activity of aleglitazar (0.3 or 3 mg/kg/day po for 12 days) was compared with &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt; (10 mg/kg/day po for 12 days) and fenofibrate (300 mg/kg/day po for 12 days; a PPARalpha agonist) by assessing their effects on HDL-cholesterol levels in transgenic mice overexpressing the human form of apolipoprotein A1 [&lt;ulink linkType="Reference" linkID="986398"&gt;986398&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;]. Relative to control mice (presumably untreated), plasma HDL-cholesterol levels increased by &amp;gt; 90% with fenofibrate, &amp;gt; 25% with 3 mg/kg/day of aleglitazar and by ~ 10% with 0.3 mg/kg/day of aleglitazar; &lt;ulink linkType="Drug" linkID="14652"&gt;farglitazar&lt;/ulink&gt; did not have any effect. Plasma lipid distribution was analyzed using a fast-protein liquid chromatography method and demonstrated that the 3-mg/kg/day dose of aleglitazar shifted lipids to the fraction of larger HDL particles in a manner similar to fenofibrate [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effects of aleglitazar (0.03 mg/kg po, qd for 6 weeks) on PPARalpha-mediated lipid metabolism and PPARgamma-mediated glycemic effects were assessed in obese, hypertriglyceridemic and insulin-resistant rhesus monkeys [&lt;ulink linkType="Reference" linkID="1046914"&gt;1046914&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1054544"&gt;1054544&lt;/ulink&gt;]. Compared with baseline, administration of aleglitazar resulted in significant and robust changes in lipid levels, including reductions in LDL-cholesterol (37%), VLDL-cholesterol (90%), triglycerides (88%) and apolipoprotein B (54%), and a significant increase in HDL-cholesterol (109%) [&lt;ulink linkType="Reference" linkID="1054544"&gt;1054544&lt;/ulink&gt;]. These changes were accompanied by insulin-sensitizing and glucose-lowering effects; aleglitazar increased the GIR by 60% and reduced fasting plasma glucose by 17%. The body weight of monkeys was also reduced by ~ 4.8% [&lt;ulink linkType="Reference" linkID="104619"&gt;104619&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1054544"&gt;1054544&lt;/ulink&gt;]. Moreover, fasting insulin and HbA1c levels were reduced by 61 and 13%, respectively [&lt;ulink linkType="Reference" linkID="1046914"&gt;1046914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In obese, hypertriglyceridemic and insulin-resistant rhesus monkeys receiving aleglitazar (0.03 mg/kg po, qd for 6 weeks), assessment of biochemistry and hematology profiles indicated no concern for safety, and no signs of peripheral edema were observed [&lt;ulink linkType="Reference" linkID="1046914"&gt;1046914&lt;/ulink&gt;]. It should be mentioned that the emergence of cardiovascular risks associated with PPARgamma, such as edema and hemodilution, depend on the duration of exposure to the agent and the dose. Studies of at least 1 year would be needed to adequately assess the toxicity of aleglitazar.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;Following treatment of rats and cynomolgus monkeys with aleglitazar (no further details specified), the total clearance was 6.2 and 1.6 ml/min/kg, respectively, the bioavailability was 70 and 68%, respectively, and the t1/2 value was 4 and 12.9 h, respectively [&lt;ulink linkType="Reference" linkID="1003790"&gt;1003790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial, aleglitazar (20 to 900 microg po, qd) was administered to patients (n = 71) with T2DM for 6 weeks [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;]. Peak plasma concentrations were reached after ~ 3 h and the mean apparent t1/2 value of aleglitazar ranged from 5 to 16 h. Aleglitazar exposure increased dose-dependently after a single dose on day 1 and at steady-state on day 43, and no accumulation of aleglitazar was observed. At steady-state, Cmax values ranged from 1.1 to 49.2 ng/ml with 20 to 900 microg of aleglitazar and AUC0-24 h values ranged from 8.66 to 402 ng.h/ml. Aleglitazar was excreted unchanged in the urine; the apparent clearance of aleglitazar was unaffected by the dose (ranging between 1.92 l/h at 50 microg to 2.95 l/h at 600 microg), while the volume of distribution increased dose-dependently (ranging from 20.1 to 52.9 l at 20 to 900 microg) [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, randomized, two-cohort, open-label, three-period, three-way crossover clinical trial assessed aleglitazar (300 microg po, qd) with or without the statins &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; (80 mg qd) or &lt;ulink linkType="Drug" linkID="12420"&gt;rosuvastatin&lt;/ulink&gt; (40 mg qd) in healthy volunteers (n = 44) [&lt;ulink linkType="Reference" linkID="1054395"&gt;1054395&lt;/ulink&gt;]. Pharmacokinetics of each drug were assessed on day 7 of each dosing period. There were no clinically relevant effects on steady-state pharmacokinetics of aleglitazar or either statin following coadministration. The peak and total exposure to aleglitazar and each statin were not altered when the drugs were administered alone or in combination [&lt;ulink linkType="Reference" linkID="1054395"&gt;1054395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, open-label, parallel-group clinical trial (&lt;ulink linkType="Protocol" linkID="70216"&gt;NCT01197911&lt;/ulink&gt;; BP25240) was also planned; this trial would assess the pharmacokinetics and safety of a single oral dose of aleglitazar in healthy volunteers and in volunteers with mild or moderate hepatic impairment (expected total n = 40). The trial had an estimated completion date of September 2011.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial assessed multiple ascending doses of aleglitazar (20, 50, 100, 300, 600 and 900 microg po, qd) for 6 weeks in patients (n = 71) with T2DM (time since diagnosis ranged from 1 to 21 years) [&lt;ulink linkType="Reference" linkID="1046913"&gt;1046913&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;]. Dose-dependent changes were observed in fasting and postprandial glucose levels and insulin-resistance following aleglitazar treatment. After 6 weeks, significant percentage changes from baseline were achieved with doses &gt;/= 300 microg of aleglitazar in the area of glucose effect (AOEglucose; reductions of ~ 18 to 35%), fasting plasma glucose (reductions of ~ 15 to 32%; differences apparent after 2 weeks) and HOMA-IR (reductions of ~ 28 to 60%). Lipid parameters also improved dose-dependently. Percentage change reductions from baseline of &gt;/= 10% were noted at doses &gt;/= 50 microg of aleglitazar for triglycerides, at doses &gt;/= 100 microg for free fatty acids and at doses &gt;/= 300 microg for LDL-cholesterol. A percentage change increase from baseline of &gt;/= 10% in HDL-cholesterol was apparent at doses &gt;/= 50 microg of aleglitazar [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additionally, two phase I, randomized, double-blind, placebo-controlled, parallel-group, single-center clinical trials were to assess aleglitazar (150 microg po, qd) in healthy volunteers (expected n = 44 in both trials) in combination with aspirin (325 mg po, qd; &lt;ulink linkType="Protocol" linkID="69514"&gt;NCT01188304&lt;/ulink&gt;; BP25329) and ibuprofen (po, qd; &lt;ulink linkType="Protocol" linkID="69518"&gt;NCT01188317&lt;/ulink&gt;; BP25330) for 13 and 12 weeks, respectively. In both trials, the primary endpoint was the effect of the respective combination on the GFR. Secondary endpoints included effects of the combinations on renal plasma flow, the renin-angiotensin system and platelet function, the pharmacokinetics of aleglitazar coadministered with aspirin/ibuprofen, and the safety of aleglitazar. At the time of publication, recruitment to &lt;ulink linkType="Protocol" linkID="69514"&gt;NCT01188304&lt;/ulink&gt; had been completed, but was ongoing in &lt;ulink linkType="Protocol" linkID="69518"&gt;NCT01188317&lt;/ulink&gt;. The estimated completion date of &lt;ulink linkType="Protocol" linkID="69514"&gt;NCT01188304&lt;/ulink&gt; was October 2010 and of &lt;ulink linkType="Protocol" linkID="69518"&gt;NCT01188317&lt;/ulink&gt; was November 2010.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="3329"&gt;NCT00388518&lt;/ulink&gt;; BM17864; SYNCHRONY) compared aleglitazar (50, 150, 300 and 600 microg po, qd; administered 4 to 5 weeks after a single-blind, placebo run-in period) with open-label &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg po, qd) in patients (n = 332; aged 18 to 75 years) with T2DM (time since diagnosis ranged from 0.1 to 38 years) for 16 weeks [&lt;ulink linkType="Reference" linkID="1013472"&gt;1013472&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046913"&gt;1046913&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1053730"&gt;1053730&lt;/ulink&gt;]. Criteria for inclusion were levels of HbA1c &amp;lt;/= 10% at screening and between 7 to 10% at the pre-randomization visit, fasting plasma glucose levels &amp;gt; 7.0 mmol/l at screening and &amp;lt;/= 13.3 mmol/l at the pre-randomization visit, and patients had to be either drug-naive or taking two or fewer antihyperglycemic medications. Exclusion criteria were type 1 diabetes mellitus, impaired liver and renal function, anemia, uncontrolled hypertension, and any clinically significant cardiovascular disease [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Aleglitazar decreased HbA1c and fasting plasma glucose levels in a dose-dependent manner [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;]. The 150-microg dose of aleglitazar was comparable with the 45-mg dose of &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; in respect of the lowering of HbA1c and fasting plasma glucose levels. Reductions from baseline in HbA1c levels versus placebo after 16 weeks of treatment with 50, 150, 300 and 600 microg of aleglitazar were 0.36, 0.85, 0.96 and 1.35%, respectively, compared with -0.71% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1013472"&gt;1013472&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046917"&gt;1046917&lt;/ulink&gt;] and reductions from baseline in fasting plasma glucose levels versus placebo were ~ 1, 2.16, 2.21 and 3.3 mM, respectively, compared with 2.1 mM with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;]. Aleglitazar also dose-dependently improved lipid parameters. After 16 weeks of treatment, significant decreases versus placebo in the levels of triglycerides (27.8 to 51.6% at 50 to 600 microg of aleglitazar versus 22.3% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;), LDL-cholesterol (9 to 25.9% versus 0.2% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;) and apolipoprotein B (14.1 to 30.5% versus 7.15% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;) were observed as well as significant increases versus placebo in the levels of HDL-cholesterol (8.2 to 21.7% versus 12.1% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="1013472"&gt;1013472&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046917"&gt;1046917&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An additional analysis of the SYNCHRONY trial assessed the effects of aleglitazar on several cardiovascular markers of inflammation and clotting, such as high sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor 1 (PAI-1) and fibrinogen [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1053730"&gt;1053730&lt;/ulink&gt;]. Beneficial effects on cardiovascular markers were observed after 16 weeks of treatment at doses &gt;/= 150 microg of aleglitazar. The absolute median change from baseline versus placebo in hsCRP was -0.11, -0.64, -0.56, -1.70 and -0.86 with 50, 150, 300 and 600 microg of aleglitazar and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;, respectively. The respective absolute changes from baseline versus placebo for PAI-1 were -2.2, -1.3, -5.1, -5.3 and -3.6, respectively, and for fibrinogen were -21.6, -36.5, -38.3, -79 and +7.9, respectively [&lt;ulink linkType="Reference" linkID="1053730"&gt;1053730&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II, randomized, double-blind, active-controlled, parallel-group, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="3333"&gt;NCT00461006&lt;/ulink&gt;; BC20653; SESTRA-R) compared aleglitazar (600 microg po, qd) with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg po, qd) in patients (n = 176) with T2DM for up to 52 weeks. The primary endpoint was the relative change from baseline in the GFR at week 26. Secondary endpoints included changes from baseline in effective renal plasma flow and in the urine albumin-to-creatinine ratio at week 26, absolute changes in HbA1c, fasting plasma glucose and fasting plasma insulin levels at the end of treatment, and side effects throughout the trial. At the time of publication, results were available from the analysis of the renal function and adverse events [&lt;ulink linkType="Reference" linkID="1135694"&gt;1135694&lt;/ulink&gt;] and are discussed in the Side effects and contraindications section. Preliminary results from efficacy measures at week 26 demonstrated a mean change in HbA1c levels of -0.95% with aleglitazar and -0.79% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1135694"&gt;1135694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II, randomized, double-blind, active-controlled, parallel-group, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="63256"&gt;NCT01043029&lt;/ulink&gt;; BC22419; 2009-012270-12; ALENEPHRO) was to compare aleglitazar (150 microg po, qd) with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg po, qd) in patients (expected n = 300) with T2DM and moderate renal impairment for 52 weeks. The primary endpoint was the GFR at week 60. Secondary endpoints included the GFR at week 52, the effect on blood hemoglobin, and safety and tolerability. At the time of publication, recruitment was ongoing and the trial had an estimated completion date of February 2013.&lt;/para&gt;&lt;para&gt;A phase II, randomized, double-blind, active-controlled, parallel-group, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="3334"&gt;NCT00461058&lt;/ulink&gt;; BC20265) was to compare aleglitazar (up to 300 microg po, qd) with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg po, qd) in patients (expected n = 100 to 500) with T2DM and class II heart failure for up to 52 weeks. The primary endpoints were the incidence of cardiovascular death, hospitalization or clinic visits for heart failure. Secondary endpoints included safety (eg, peripheral edema, increase in body weight and side effects) and efficacy (eg, change from baseline to end of treatment in HbA1c, fasting plasma glucose and fasting plasma insulin levels, and lipid profile) parameters. The trial was terminated because of cardiovascular safety concerns associated with TZDs in patients with symptomatic class II heart failure.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="63253"&gt;NCT01042769&lt;/ulink&gt;; BC22140; 2009-012269-71; ALECARDIO) was to assess the potential of aleglitazar (150 microg po, qd) to reduce cardiovascular risk in patients (expected n = 6000) with T2DM who had recently experienced a cardiac event. The primary endpoints were the effect on cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and other (unspecified) cardiovascular endpoints throughout the trial period of approximately 4.5 years. Secondary endpoints included the glycemic control, lipoprotein profile, blood pressure and biomarkers of cardiovascular risk. At the time of publication, recruitment was ongoing and the trial had an estimated completion date of July 2014.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In the phase I clinical trial that assessed aleglitazar with or without the statins &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="12420"&gt;rosuvastatin&lt;/ulink&gt;, no notable differences in the adverse events between treatments were observed in healthy volunteers. There were no clinically significant changes in vital signs, ECG or laboratory parameters for any of the treatments [&lt;ulink linkType="Reference" linkID="1054395"&gt;1054395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I clinical trial in patients with T2DM, aleglitazar (20 to 900 microg) was well tolerated [&lt;ulink linkType="Reference" linkID="1046913"&gt;1046913&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;]. The most frequent adverse events in both the placebo and aleglitazar groups were edema (all mild and independent of aleglitazar dose), hyperglycemia, headache, gastrointestinal disorders and fatigue. A dose-dependent decrease in systolic and diastolic blood pressure was observed with significant differences from placebo of ~ 10 and 6 mmHg in systolic and diastolic blood pressure, respectively, at doses &gt;/= 300 microg of aleglitazar. Moderate dose-dependent decreases were also noted in hematocrit, hemoglobin, and red and white blood cell counts, as well as an increase of &amp;gt; 1 kg in body weight at doses &gt;/= 600 microg of aleglitazar. In addition, an adverse effect on renal function was observed, as assessed by increased levels of creatine phosphokinase ranging from a 4-fold increase versus placebo at 20 microg of aleglitazar to a 10-fold increase at 900 microg of aleglitazar [&lt;ulink linkType="Reference" linkID="1120925"&gt;1120925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II clinical trial (&lt;ulink linkType="Protocol" linkID="3329"&gt;NCT00388518&lt;/ulink&gt;; SYNCHRONY) in patients with T2DM, all doses of aleglitazar (50 to 600 microg) were well tolerated and a similar number of patients had adverse events with aleglitazar (21 to 26 of 55 patients per dose level), placebo (25 of 55 patients) and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (30 of 57 patients) [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;]. At 150 microg of aleglitazar, the dose that is comparable in efficacy with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg), adverse events associated with PPARgamma activation were less than with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;; events measured versus baseline were the effect of body weight gain (0.52 versus 1.06 kg), the effect on hemoglobin levels (-4.80 versus -6.12 g/l) and the incidence of peripheral edema (2 versus 4 cases) [&lt;ulink linkType="Reference" linkID="1013472"&gt;1013472&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046917"&gt;1046917&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1053730"&gt;1053730&lt;/ulink&gt;]. An increase in the levels of serum creatinine (an adverse event associated with PPARalpha activation), indicating impairment in renal function, was also observed and occurred in a dose-dependent manner for aleglitazar. At 150 microg of aleglitazar, a change from baseline in serum creatinine levels of 7.16% was noted compared with 3.18% for &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;]. Furthermore, after treatment with aleglitazar, systolic and diastolic blood pressure were reduced. Changes in systolic blood pressure were -3.1 to -7.4 mmHg with aleglitazar, -2.6 mmHg with placebo and -5.7 mmHg with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;, and changes in diastolic blood pressure were -1.7 to -3.8 mmHg with aleglitazar, -0.9 mmHg with placebo and -4.7 mmHg with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1016873"&gt;1016873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II clinical trial (&lt;ulink linkType="Protocol" linkID="3333"&gt;NCT00461006&lt;/ulink&gt;; SESTRA-R) comparing aleglitazar (600 microg) with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (45 mg) in patients with T2DM, adverse events were observed in 51 aleglitazar-treated patients (59%) and 39 &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;-treated patients (44%) [&lt;ulink linkType="Reference" linkID="1135964"&gt;1135964&lt;/ulink&gt;]. The majority of adverse events were mild and consistent with recognized adverse effects of PPARgamma agonists. The most common adverse event was peripheral edema, which occurred in 19 patients receiving aleglitazar (13 cases were of mild and 6 of moderate intensity) and 9 patients receiving &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (8 mild and one severe). The mean increase in body weight was greater with aleglitazar (3.45 kg) compared with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (1.93 kg) as were decreases in hemoglobin levels (-1.33 versus -0.56 g/dl). Systolic and diastolic blood pressure were reduced by both aleglitazar (-3.8 and -2.5 mmHg, respectively) and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; (-2.25 and -2.7 mmHg, respectively) [&lt;ulink linkType="Reference" linkID="1135964"&gt;1135964&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from the analysis of the renal function were available for 118 evaluable patients [&lt;ulink linkType="Reference" linkID="1135964"&gt;1135964&lt;/ulink&gt;]. At week 26, the change from baseline in the mean GFR (mGFR) was -16.9% with aleglitazar and -4.6% with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;. The percentage changes from baseline over time in the estimated GFR (eGFR) were -19.2 and 1.3%, respectively. Both mGFR and eGFR were similarly reduced at week 12 (time of first postbaseline assessment) and week 26, reached a plateau after 4 weeks and returned to baseline levels following cessation of treatment. A total of 20 patients receiving aleglitazar and 10 patients receiving &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; were withdrawn from the trial. Of the aleglitazar-treated patients, five withdrew because of renal safety concerns; none of the &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;-treated patients withdrew for this reason. Two aleglitazar-treated patients that withdrew had a peripheral edema, in one of whom the greatest increase in serum creatinine levels (78.5% from baseline) was observed; the level of serum creatinine returned to baseline upon treatment withdrawal. Overall, six other aleglitazar-treated patients had increases in serum creatinine levels &amp;gt; 50% from baseline; in five of whom the levels returned to pretreatment levels following withdrawal of treatment [&lt;ulink linkType="Reference" linkID="1135694"&gt;1135694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;Aleglitazar was specifically claimed by &lt;ulink linkType="Company" linkID="19446"&gt;Roche Holding&lt;/ulink&gt; in &lt;ulink linkType="Patent" linkID="PA170300"&gt;WO-02092084&lt;/ulink&gt; (claim 14, third compound), which has been granted in the US as &lt;ulink linkType="Patent" linkID="PA3087116"&gt;US-06642389&lt;/ulink&gt; (claim 23) and Europe as &lt;ulink linkType="Patent" linkID="PA3314447"&gt;EP-01392295&lt;/ulink&gt; (claim 15); both are due to expire in May 2022.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="19446"&gt;Roche Holding&lt;/ulink&gt; has since claimed methods for the preparation of chiral propionic acid derivatives, including aleglitazar, in &lt;ulink linkType="Patent" linkID="PA2959246"&gt;WO-2005030764&lt;/ulink&gt;, and tablet formulations of aleglitazar in &lt;ulink linkType="Patent" linkID="PA5660596"&gt;WO-2010084066&lt;/ulink&gt;. &lt;ulink linkType="Patent" linkID="PA2959246"&gt;WO-2005030764&lt;/ulink&gt; has been granted as &lt;ulink linkType="Patent" linkID="PA3259017"&gt;EP-01670792&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3561569"&gt;US-07365207&lt;/ulink&gt; (both due to expire in September 2024) and &lt;ulink linkType="Patent" linkID="PA2958778"&gt;US-07262303&lt;/ulink&gt; (due to expire in February 2026, following US154 extension).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;The development of a dual PPARalpha/gamma agonist to treat patients with T2DM is an attractive alternative for the treatment of a complexity of pathologies of this disease. However, the development of &lt;ulink linkType="Drug" linkID="33451"&gt;muraglitazar&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt;, the only PPARalpha/gamma agonists until recently to have reached phase III clinical trials, has been discontinued because of safety concerns. In phase III trials, &lt;ulink linkType="Drug" linkID="17061"&gt;tesaglitazar&lt;/ulink&gt; increased serum creatinine levels and decreased the glomerular filtration rate (GFR) [&lt;ulink linkType="Reference" linkID="665830"&gt;665830&lt;/ulink&gt;], whereas &lt;ulink linkType="Drug" linkID="33451"&gt;muraglitazar&lt;/ulink&gt; increased the risk of cardiovascular events [&lt;ulink linkType="Reference" linkID="630997"&gt;630997&lt;/ulink&gt;]. Moreover, both dual PPARalpha/gamma agonists demonstrated increased carcinogenicity in rodents [&lt;ulink linkType="Reference" linkID="826754"&gt;826754&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="826783"&gt;826783&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Several novel dual/triple PPARalpha/gamma/delta agonists are currently in clinical development, such as aleglitazar, &lt;ulink linkType="Drug" linkID="49998"&gt;lobeglitazone&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="15410"&gt;Chong Kun Dang Pharmaceutical&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1053023"&gt;1053023&lt;/ulink&gt;]), &lt;ulink linkType="Drug" linkID="51233"&gt;CS-038&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="1008516"&gt;Shenzhen Chipscreen Biosciences&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1001742"&gt;1001742&lt;/ulink&gt;]), &lt;ulink linkType="Drug" linkID="47643"&gt;indeglitazar&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="29155"&gt;Plexxikon&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1101046"&gt;1101046&lt;/ulink&gt;]) and &lt;ulink linkType="Drug" linkID="53444"&gt;DSP-8658&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="1017117"&gt;Dainippon Sumitomo Pharma&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1097305"&gt;1097305&lt;/ulink&gt;]). Of these, only aleglitazar and &lt;ulink linkType="Drug" linkID="49998"&gt;lobeglitazone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1053023"&gt;1053023&lt;/ulink&gt;] have advanced into phase III clinical trials. Data on &lt;ulink linkType="Drug" linkID="49998"&gt;lobeglitazone&lt;/ulink&gt; are limited and aleglitazar seems to be the most promising of these agents.&lt;/para&gt;&lt;para&gt;Aleglitazar appears to be a balanced PPARalpha/gamma agonist with beneficial effects on insulin sensitivity as well as anti-atherogenic effects. When compared with the therapeutically recommended dose of 45 mg of &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;, a dose of 150 microg of aleglitazar appeared to be equally efficacious with respect to glucose clearance and insulin sensitization. In addition, aleglitazar had a favorable lipid profile, which includes a decrease in LDL-cholesterol, triglycerides and apolipoprotein B, and an increase in HDL-cholesterol. The adverse effects of aleglitazar are characteristic for both PPARgamma agonists (ie, TZDs) and PPARalpha agonists (ie, fibrates). These include edema, weight gain and effects on renal function as measured by increased levels of serum creatinine. Of these, edema and weight gain appear to be milder than with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;; however, the increase in creatinine is of concern. The two phase II clinical trials SESTRA-R and ALENEPHRO, which have primary endpoints of changes from baseline in GFR, should assess this risk more adequately. Results from the SESTRA-R trial had just become available at the time of publication and demonstrated that reductions in GFR and increases in serum creatinine levels were more pronounced with aleglitazar than with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;. These effects were reversible upon treatment cessation. The aleglitazar dose used in the SESTRA-R trial was higher (600 microg) than the dose (150 microg) that resulted in comparable efficacy with &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;. The SYNCHRONY trial demonstrated a dose-dependent renal effect, with a dose of 150 microg showing a tendency to decreased renal function. The SESTRA-R trial confirmed that doses of aleglitazar &amp;gt; 150 microg have an adverse effect on renal function. The duration of both trials was relatively short (SYNCHRONY for 16 weeks, SESTRA-R for 26 weeks) and concerns remain regarding the long-term effects of aleglitazar. In the view of the SYNCHRONY and SESTRA-R trials, there is not enough information to assess dose-dependent and long-term effects of aleglitazar on renal function. Furthermore, preclinical studies to evaluate possible carcinogenicity of aleglitazar should be conducted.&lt;/para&gt;&lt;para&gt;The major concern with aleglitazar is that the developer &lt;ulink linkType="Company" linkID="19446"&gt;Roche Holding&lt;/ulink&gt; has, to date, not considered a clinical trial to assess the risk of bone fractures. This is surprising given the compelling evidence that PPARgamma agonists (ie, &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt;) cause bone loss and increase fracture risk in humans [&lt;ulink linkType="Reference" linkID="1043653"&gt;1043653&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129757"&gt;1129757&lt;/ulink&gt;]. In bone, PPARgamma controls the development of bone cells and the cytokine milieu of the bone marrow environment [&lt;ulink linkType="Reference" linkID="550982"&gt;550982&lt;/ulink&gt;]. PPARgamma activation leads to unbalanced bone remodeling with bone resorption increases and bone formation decreases [&lt;ulink linkType="Reference" linkID="1043653"&gt;1043653&lt;/ulink&gt;]. The observed bone loss in users of TZDs occurs at a rate of approximately 1% annually as compared with non-TZD users and is associated with changes in the levels of circulating bone turnover markers [&lt;ulink linkType="Reference" linkID="729047"&gt;729047&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The causal connection between TZD therapy and increased fracture risk was determined in a number of clinical trials, which were either retrospective or observational, and included an analysis of trials designed to assess the antidiabetic efficacy of TZDs or analyses of large national or regional databases (eg, the UK General Practice Research Database) [&lt;ulink linkType="Reference" linkID="975293"&gt;975293&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129666"&gt;1129666&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129670"&gt;1129670&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129748"&gt;1129748&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129750"&gt;1129750&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129751"&gt;1129751&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129752"&gt;1129752&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129755"&gt;1129755&lt;/ulink&gt;]. In general, both &lt;ulink linkType="Drug" linkID="8976"&gt;rosiglitazone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4126"&gt;pioglitazone&lt;/ulink&gt; increased the risk of non-vertebral fractures, including fractures of upper and lower limbs, by approximately 2-fold. The risk factors include: (i) gender - women are at increased risk of bone loss and fractures [&lt;ulink linkType="Reference" linkID="975293"&gt;975293&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129748"&gt;1129748&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129751"&gt;1129751&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129752"&gt;1129752&lt;/ulink&gt;], although some studies suggest an equal risk in both genders [&lt;ulink linkType="Reference" linkID="1129666"&gt;1129666&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129670"&gt;1129670&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129750"&gt;1129750&lt;/ulink&gt;]; (ii) age - women over the age of 65 years appeared to be at the greatest risk for fractures [&lt;ulink linkType="Reference" linkID="1129748"&gt;1129748&lt;/ulink&gt;] and the risk increases by 2% for every year increase in age [&lt;ulink linkType="Reference" linkID="1129752"&gt;1129752&lt;/ulink&gt;]; (iii) the risk of fractures increases with the duration of treatment [&lt;ulink linkType="Reference" linkID="1129670"&gt;1129670&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1129752"&gt;1129752&lt;/ulink&gt;]; and (iv) the risk of fractures is increased in individuals who have a history of prior TZD-unrelated fractures [&lt;ulink linkType="Reference" linkID="1129755"&gt;1129755&lt;/ulink&gt;]. Based on these evidences, the TZDs, as a class of PPARgamma agonists, are considered as a class of drugs causing secondary osteoporosis [&lt;ulink linkType="Reference" linkID="1129757"&gt;1129757&lt;/ulink&gt;] and the FDA issued a warning that available TZDs may have adverse effects on bone [&lt;ulink linkType="Reference" linkID="1130848"&gt;1130848&lt;/ulink&gt;]. In view of this warning, assessment of bone safety is highly warranted and necessary for new PPARgamma agonists, such as aleglitazar.&lt;/para&gt;&lt;para&gt;Overall, aleglitazar is a promising novel PPARalpha/gamma agonist with antidiabetic activities and the potential to reduce the risk of cardiovascular disease in patients with high-risk T2DM. The ongoing trials should address some of the safety concerns, including renal function, but further studies are needed to clarify the effect on bone and potential carcinogenicity of aleglitazar.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-10T00:00:00.000Z</StatusDate><Source id="1450687" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-16T00:00:00.000Z</StatusDate><Source id="819104" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-16T00:00:00.000Z</StatusDate><Source id="819104" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-16T00:00:00.000Z</StatusDate><Source id="819104" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-03-01T12:58:07.000Z</StatusDate><Source id="441654" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-18T00:00:00.000Z</StatusDate><Source id="1083167" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-01-17T00:00:00.000Z</StatusDate><Source id="1083854" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-03-31T00:00:00.000Z</StatusDate><Source id="485279" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-18T00:00:00.000Z</StatusDate><Source id="732443" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="WO">World</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-16T00:00:00.000Z</StatusDate><Source id="819104" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01593"><Name>PPAR alpha</Name><SwissprotNumbers><Swissprot>O35507</Swissprot><Swissprot>P23204</Swissprot><Swissprot>P37230</Swissprot><Swissprot>P37232</Swissprot><Swissprot>Q07869</Swissprot><Swissprot>Q8HYL6</Swissprot><Swissprot>Q95N78</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01596"><Name>PPAR gamma</Name><SwissprotNumbers><Swissprot>O18924</Swissprot><Swissprot>O18971</Swissprot><Swissprot>O19052</Swissprot><Swissprot>O62807</Swissprot><Swissprot>O88275</Swissprot><Swissprot>P37231</Swissprot><Swissprot>P37234</Swissprot><Swissprot>P37238</Swissprot><Swissprot>P57797</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1c(nc(o1)c2ccccc2)CCOc3ccc(c4c3ccs4)C[C@@H](C(=O)O)OC</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1733894" number="WO-2005030764" title="Process for the preparation of chiral propionic acid derivatives"></PatentFamily><PatentFamily id="2249919" number="WO-02092084" title="Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes"></PatentFamily><PatentFamily id="2343922" number="WO-2010084066" title="Pharmaceutical composition comprising aleglitazar"></PatentFamily><PatentFamily id="2646958" number="WO-2013181384" title="Solid state forms of aleglitazar sodium"></PatentFamily><PatentFamily id="2674832" number="WO-2014016369" title="Pharmaceutical formulation comprising aleglitazar and a complexing agent"></PatentFamily><PatentFamily id="2675267" number="WO-2014016371" title="Micronized aleglitazar"></PatentFamily><PatentFamily id="2675269" number="WO-2014016370" title="Amorphous aleglitazar"></PatentFamily><PatentFamily id="2698890" number="WO-2014040936" title="Solid forms of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[B]thiophen-7-yl}-propionic acid and of salts thereof"></PatentFamily><PatentFamily id="3668392" number="WO-2017084989" title="Aleglitazar for the treatment of diabetic kidney disease"></PatentFamily><PatentFamily id="966454" number="WO-2010108861" title="Process for the preparation of propionic acid derivatives"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>